Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer

Background/Aims: Autologous, tumor-derived, heat shock protein gp96 peptide complexes have antitumor potential. We conducted the first Phase II trial to evaluate the safety and efficacy of gp96 vaccination in adjuvant settings for patients with gastric cancer. Methods: We enrolled 73 consecutive pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kecheng, Peng, Zheng, Huang, Xiaohui, Qiao, Zhi, Wang, Xinxin, Wang, Ning, Xi, Hongqing, Cui, Jianxin, Gao, Yunhe, Huang, Xijian, Gao, Hua, Wei, Bo, Chen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556646/
https://www.ncbi.nlm.nih.gov/pubmed/28819380
http://dx.doi.org/10.7150/jca.18946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556646/
https://www.ncbi.nlm.nih.gov/pubmed/28819380
http://dx.doi.org/10.7150/jca.18946

Ejemplares similares